Can Patients with Ehlers-Danlos Syndrome Use NAD-Boosting Supplements?
Yes, patients with Ehlers-Danlos syndrome can safely use NAD-boosting supplements based on available safety data, though there is no specific evidence demonstrating therapeutic benefit for EDS symptoms.
Safety Profile
NAD+ precursors (nicotinamide riboside and nicotinamide mononucleotide) have been studied in human trials and demonstrate good safety and tolerability profiles 1. These compounds successfully raise NAD+ levels in multiple tissues without significant adverse effects across various populations including healthy adults and those with cardiometabolic conditions 1.
Lack of EDS-Specific Evidence
No published research exists examining NAD+ supplementation specifically in EDS patients. The available guidelines and research on EDS management do not mention NAD+ boosting compounds at all:
The 2025 AGA guidelines on hypermobile EDS focus on gastrointestinal manifestations, POTS, and mast cell activation syndrome, recommending dietary interventions like gastroparesis diets and elimination diets (low-FODMAP, low-histamine) but make no reference to NAD+ supplementation 2
A 2005 hypothesis paper proposed nutritional supplements for EDS (vitamin C, coenzyme Q10, glucosamine, magnesium, and others) but did not include NAD+ precursors 3
Recent comprehensive treatment reviews and international guidelines from China covering 24 medical specialties do not mention NAD+ supplementation 4, 5
Clinical Considerations
What to Monitor
If prescribing NAD+ supplements to EDS patients, be aware of:
Mast cell activation concerns: Many hEDS patients have comorbid MCAS, which can be triggered by various supplements and medications 2. Start with lower doses and monitor for histamine-mediated reactions
Gastrointestinal symptoms: 98% of hEDS patients meet criteria for disorders of gut-brain interaction 2. NAD+ supplements are generally well-tolerated gastrointestinally 1, but individual responses vary
Drug interactions: While NAD+ precursors have good safety profiles, patients with EDS often take multiple medications for pain management (neuropathic modulators, muscle relaxants) 4
Dosing Considerations
Published human trials use varying regimens, typically nicotinamide riboside 250-1000 mg daily or nicotinamide mononucleotide 250-500 mg daily 1. Given the lack of EDS-specific data, start at the lower end of studied doses and titrate based on tolerance.
Important Caveats
Do not position NAD+ supplementation as treatment for EDS symptoms. While NAD+ precursors show promise in aging and metabolic research, there is no evidence they address the underlying collagen abnormalities, joint hypermobility, tissue fragility, or pain that characterize EDS 1, 3.
The evidence-based nutritional approaches for EDS patients remain focused on addressing specific comorbidities: gastroparesis diets for delayed gastric emptying, low-histamine diets for MCAS, and nutritional counseling to prevent restrictive eating patterns 2, 6.